12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VS-6063: Phase I data

Data from 6 patients with advanced ovarian cancer in the dose-escalation Phase I portion of an open-label, U.S. Phase I/Ib trial showed that doses of up to twice-daily 400 mg oral VS-6063 plus IV paclitaxel on days 1, 8 and 15 of...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >